Switch theme
Sign up to access all valuation multiples
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
1990
859
LTM Revenue $229M
LTM EBITDA $78.1M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Caplin Point Laboratories has a last 12-month revenue of $229M and a last 12-month EBITDA of $78.1M.
In the most recent fiscal year, Caplin Point Laboratories achieved revenue of $195M and an EBITDA of $71.9M.
Caplin Point Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Caplin Point Laboratories valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $170M | $195M | XXX | XXX | XXX |
| Gross Profit | $81.6M | $93.3M | XXX | XXX | XXX |
| Gross Margin | 48% | 48% | XXX | XXX | XXX |
| EBITDA | $57.7M | $71.9M | XXX | XXX | XXX |
| EBITDA Margin | 34% | 37% | XXX | XXX | XXX |
| Net Profit | $34.8M | $43.7M | XXX | XXX | XXX |
| Net Margin | 20% | 22% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Caplin Point Laboratories's stock price is INR 1869 (or $22).
Caplin Point Laboratories has current market cap of INR 142B (or $1.7B), and EV of INR 133B (or $1.5B).
See Caplin Point Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.7B | XXX | XXX | XXX | XXX | $0.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Caplin Point Laboratories has market cap of $1.7B and EV of $1.5B.
Caplin Point Laboratories's trades at 6.8x LTM EV/Revenue multiple, and 19.8x LTM EBITDA.
Analysts estimate Caplin Point Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Caplin Point Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 20.3x | XXX | XXX | XXX |
| P/E | 27.3x | XXX | XXX | XXX |
| P/E/Growth | 1.7x | XXX | XXX | XXX |
| EV/FCF | 44.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCaplin Point Laboratories's NTM/LTM revenue growth is 15%
Caplin Point Laboratories's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Caplin Point Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Caplin Point Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Caplin Point Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 49% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caplin Point Laboratories acquired XXX companies to date.
Last acquisition by Caplin Point Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Caplin Point Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Caplin Point Laboratories founded? | Caplin Point Laboratories was founded in 1990. |
| Where is Caplin Point Laboratories headquartered? | Caplin Point Laboratories is headquartered in India. |
| How many employees does Caplin Point Laboratories have? | As of today, Caplin Point Laboratories has 859 employees. |
| Is Caplin Point Laboratories publicy listed? | Yes, Caplin Point Laboratories is a public company listed on BOM. |
| What is the stock symbol of Caplin Point Laboratories? | Caplin Point Laboratories trades under 524742 ticker. |
| When did Caplin Point Laboratories go public? | Caplin Point Laboratories went public in 2001. |
| Who are competitors of Caplin Point Laboratories? | Similar companies to Caplin Point Laboratories include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Caplin Point Laboratories? | Caplin Point Laboratories's current market cap is $1.7B |
| What is the current revenue of Caplin Point Laboratories? | Caplin Point Laboratories's last 12-month revenue is $229M. |
| What is the current EBITDA of Caplin Point Laboratories? | Caplin Point Laboratories's last 12-month EBITDA is $78.1M. |
| What is the current EV/Revenue multiple of Caplin Point Laboratories? | Current revenue multiple of Caplin Point Laboratories is 6.8x. |
| What is the current EV/EBITDA multiple of Caplin Point Laboratories? | Current EBITDA multiple of Caplin Point Laboratories is 19.8x. |
| What is the current revenue growth of Caplin Point Laboratories? | Caplin Point Laboratories revenue growth between 2023 and 2024 was 14%. |
| Is Caplin Point Laboratories profitable? | Yes, Caplin Point Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
